ArticleTobacco induced diseases2025
Tobacco carcinogen NNK promotes pancreatic cancer proliferation via LINC00857/β-catenin.
Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multi-omics and radiogenomic profiling decodes NNK-related tumor remodeling and prognostic stratification in pancreatic cancer.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSmoking is a key risk factor for pancreatic cancer (PC). Nicotine-derived nitrosamine ketone (NNK), a major tobacco smoke constituent, has been shown to promote cancer growth, but its specific role in PC progression remains unclear. While long non-coding RNA LINC00857 (lnc RNA) is implicated in cancer progression, its regulation by NNK is unknown. This study aims to investigate whether NNK can drive PC growth and elucidate the underlying mechanisms.
methodsEmploying an experimental methodology, this investigation treated human pancreatic cancer cell lines (CFPAC-1 and Panc-1) with NNK and utilized various assays (CCK-8, colony formation, and EdU cell proliferation) to assess the effects on cell proliferation. The interplay between LINC00857 expression profiles, PC, and smoking was systematically investigated through cross-database bioinformatic interrogation encompassing public resources and institutional biobank data. Experiments were performed to knock down LINC00857 in PC cells using siRNA technology. We used Western blotting and quantitative real-time PCR (qRT-PCR) to assess β-catenin expression and elucidate the mechanism by which the tobacco carcinogen NNK promotes PC formation.
resultsSome evidence that NNK enhanced the proliferative capacity of PC cells was found. Bioinformatic analysis of public databases, combined with data from our center's database, revealed that LINC00857 was up-regulated in PC and correlated with smoking. Moreover, we discovered that knockdown of LINC00857 inhibited PC cell proliferation, with β-catenin identified as a potential downstream molecule. Importantly, after LINC00857 knockdown, we observed suppression of NNK-induced β-catenin upregulation at both protein and transcriptional levels.
conclusionsNNK potentially induces PC progression through the LINC00857/β-catenin axis. These findings provide new perspectives on the mechanisms of PC progression and highlight the clinical relevance of smoking cessation for preventing PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.